A four-amino-acid Khavinson bioregulator designed to restore pancreatic beta-cell function—with one rat study showing glucose reduction in diabetes and no pathway to human evidence.

Pancragen is the metabolic gateway into the Khavinson bioregulator family—the one compound in Cluster S that directly addresses blood glucose homeostasis and beta-cell function. It is a synthetic tetrapeptide consisting of four amino acids: L-lysine, L-glutamic acid, L-aspartic acid, and L-tryptophan, with an amidated C-terminus. Its molecular weight is approximately 548 daltons, making it one of the larger bioregulators in the set. For readers concerned with metabolic aging, type 2 diabetes risk, and glucose control—a much larger audience than the thymic or vascular compounds—Pancragen has immediate appeal.

The appeal rests on one animal study published in 2007. Rats given streptozotocin (a toxin that destroys beta cells and induces diabetes) and then treated with oral Pancragen showed, according to the researchers, a "pronounced hypoglycemic effect during treatment." The same rats treated with intramuscular Pancragen showed normalized capillary endothelium adhesion in mesenteric vessels—suggesting both glucose control and vascular protection. In parallel, in vitro studies show that Pancragen can stimulate CXCL12 and Hoxa3 (differentiation markers) in human embryonic pancreatic cell cultures.

But this is where the metabolic appeal meets the Khavinson Evidence Problem. Single-source data. No replication. No human trials. The bioregulator hypothesis—that a four-amino-acid peptide can penetrate pancreatic beta cells, interact with DNA, and restore age-suppressed differentiation genes—is theoretically coherent but remains experimentally unproven. Readers investing hope in Pancragen for metabolic health face the same evidence cliff as readers evaluating Vilon or Thymogen, just with higher personal stakes.

Quick Facts: Pancragen at a Glance

What Is Pancragen?

Pronunciation: PAN-kra-jen

Pancragen is a synthetic tetrapeptide—a molecule made of exactly four amino acids joined by peptide bonds: L-lysine, L-glutamic acid, L-aspartic acid, and L-tryptophan, with an amidated (modified) C-terminus. Its molecular weight is approximately 548 daltons, placing it in the mid-range of the Khavinson bioregulator family. For comparison, Vilon (the smallest) weighs ~275 Da. Thymogen weighs ~333 Da. Pancragen at 548 Da is bulkier—but still orders of magnitude smaller than mainstream peptide drugs like BPC-157 (~1419 Da) or semaglutide (~4114 Da).

Pancragen belongs to the Khavinson bioregulator family: ultrashort peptides (2–7 amino acids) developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Like all bioregulators, Pancragen is proposed to function not as a traditional receptor agonist but as an epigenetic modifier—entering cells, crossing nuclear membranes, and interacting directly with DNA to modulate gene expression in an organ-specific manner.

What distinguishes Pancragen from the other eight compounds in Cluster S is its target organ: the pancreas, specifically beta cells and glucose homeostasis. The thymic bioregulators (Vilon, Thymogen) address aging immunity. The vascular and hepatic bioregulators (Vesugen, Livagen, Ovagen) address endothelial function and liver regeneration. Pancragen is the metabolic specialist—theorized to restore the age-suppressed genes that keep beta cells functional and glucose regulation intact.

Origins and Discovery

The development of Pancragen follows the general trajectory of the Khavinson bioregulator program, but with a specific metabolic focus.

Vladimir Khavinson's initial research (1973 onward) centered on organ tissue extraction—taking peptide complexes from animal organs and testing whether they could restore function. The first successful extract was Thymalin (from calf thymus), which appeared to restore immune markers in irradiated soldiers. This success spawned a reductionist research program: identify the specific short peptides within each tissue extract that were responsible for the observed effects.

For the pancreas, researchers isolated a tetrapeptide sequence and synthesized it: Lys-Glu-Asp-Trp. The amidated C-terminus was added to enhance stability and potentially improve absorption (amidation is a standard peptide modification in pharmaceutical development). The resulting compound was named Pancragen.

Unlike the thymic bioregulators (which have decades of research history and a registered pharmaceutical status for the tissue extract version), Pancragen has a more limited publication record. The first and most significant published study appeared in 2007—PMID 18642713—in Bulletin of Experimental Biology and Medicine, testing Pancragen in a streptozotocin diabetic rat model.

Khavinson died in January 2024. Whether Pancragen research will continue or expand remains unknown.

Mechanism of Action

Pancragen's proposed mechanism follows the bioregulation paradigm, with a specific focus on pancreatic beta-cell function and glucose metabolism.

The Bioregulation Hypothesis

According to the Khavinson framework, Pancragen (Lys-Glu-Asp-Trp) enters pancreatic beta cells and crosses the nuclear membrane due to its small size (~548 Da). Once inside the nucleus, it is proposed to:

1. Bind to DNA promoter regions involved in pancreatic beta-cell development and function 2. Interact with histone proteins and chromatin structure 3. Decondense heterochromatin — converting silent, tightly packed DNA back into open, active DNA 4. Reactivate age-silenced genes involved in beta-cell differentiation — specifically genes that sustain glucose sensing, insulin secretion, and cellular survival in response to metabolic stress

The Pancreatic Specificity Question

The tetrapeptide sequence (Lys-Glu-Asp-Trp) is proposed to achieve pancreas-specific gene regulation. Three of its four amino acids (Lys, Glu, Asp) are shared with other bioregulators targeting liver (Livagen), blood vessels (Vesugen), prostate (Prostamax), and testes (Testagen). Only the C-terminal tryptophan is unique to Pancragen among the four-amino-acid Khavinson compounds. The claim is that this single amino acid difference redirects the peptide from liver-specific to pancreas-specific gene regulation—a level of specificity that has never been experimentally validated in living systems.

What the Published Data Shows

In rat studies (PMID 18642713), Pancragen administration produced measurable reductions in blood glucose in streptozotocin-diabetic rats—a functional readout, not just a gene expression assay. This is more convincing than in vitro data alone. The same study reported improved vascular endothelium function (reduced adhesion abnormalities), suggesting Pancragen may protect both glucose control and endothelial integrity—two mechanisms that are biologically linked in diabetic pathology.

In human embryonic pancreatic cells, Pancragen stimulated expression of CXCL12 (a chemokine involved in beta-cell survival and vascular development) and Hoxa3 (a transcription factor involved in pancreatic organogenesis). The effect was stronger in cells from aged donors, supporting the Khavinson hypothesis that bioregulators preferentially reactivate genes that have become silenced with age.

Key Research Areas and Studies

Glucose Lowering and Endothelial Protection in Diabetic Rats (2007)

Khavinson et al., PMID 18642713 (2007): Bulletin of Experimental Biology and Medicine 144(4):559–562. Rats were made diabetic via streptozotocin injection. Pancragen was administered via two routes: oral gavage and intramuscular injection. Results:

• Oral Pancragen produced a "pronounced hypoglycemic effect during treatment," reducing blood glucose in diabetic animals.
• Intramuscular Pancragen normalized mesenteric capillary endothelium adhesion, measured as reduced expression of adhesion molecules (ICAM-1, P-selectin) on capillary endothelial cells.
• The authors described the compound as having "homeostatic and endothelioprotective effects."

This is the only published animal efficacy study for Pancragen. It is also the only functional (glucose-lowering) endpoint in any Khavinson bioregulator study—most preclinical work measures gene expression or lifespan, not a clinically relevant metabolic parameter.

Gene Expression in Human Pancreatic Cells (In Vitro)

Pancragen stimulated expression of CXCL12 and Hoxa3 in human embryonic pancreatic cell cultures, with a stronger effect in cells derived from aged donors. These are mechanistically plausible targets (both are involved in pancreatic development and beta-cell survival), but the study design is standard in vitro work—peptide added to cells in a dish, gene expression measured via qPCR or microarray. This demonstrates the peptide can affect human pancreatic cell biology in controlled conditions. It does not demonstrate that the peptide reaches pancreatic cells, enters beta cells, or produces glucose effects when administered to a living human.

The Khavinson Evidence Problem

The Khavinson Evidence Problem applies to Pancragen with particular force, because Pancragen targets the highest-stakes metabolic condition (diabetes) with the thinnest evidence base in the entire bioregulator family.

Single-Lab Dependency

All published data on Pancragen originates from the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson until his death in 2024. No independent lab—no university, pharmaceutical company, or research institute outside Khavinson's network—has tested Pancragen's effects on glucose control, pancreatic beta-cell function, or gene expression in any model system.

Single Published Study

Unlike Vilon (which has multiple lifespan studies, tumor inhibition studies, and chromatin research) or Thymogen (which has a registered pharmaceutical status and the strongest animal lifespan study in the cluster), Pancragen has one PubMed-indexed animal study published 17 years ago. No follow-up studies. No dose-response studies. No mechanistic validation studies. A single publication in 2007.

No Western Regulatory Review

Pancragen has never been reviewed by the FDA, EMA, TGA, or Health Canada. No ClinicalTrials.gov entries. No submission to any Western pharmaceutical regulator. It is not a registered pharmaceutical in Russia (unlike Thymogen, Thymalin, or other Khavinson products).

The Metabolic Stakes Problem

Diabetes affects over 400 million people globally. Readers evaluating Pancragen are either diabetic themselves or deeply concerned about metabolic aging. This is an audience with high personal stakes—which makes the thin evidence especially problematic. A speculative peptide for immune aging or prostate health operates in a market where many readers have moderate concerns. A speculative peptide for diabetes operates in a market where readers may be desperate.

The Mechanism Specificity Question

How does a single amino acid difference (tryptophan at the C-terminus, instead of alanine or proline) redirect the peptide from liver to pancreas? The computational work predicting DNA-binding selectivity has never been published for Pancragen specifically. The direct experimental validation of DNA binding—in any tissue, in any cell type, in any living system—does not exist.

Claims vs. Evidence

The Human Evidence Landscape

There is no human clinical evidence for Pancragen. The compound has never been tested in a randomized, controlled, blinded, or dose-finding trial in humans—in any country, under any regulatory framework.

The closest thing to human relevance is the in vitro work using human embryonic pancreatic cells. Pancragen was applied to cultured cells from human donors and produced measurable changes in gene expression. This demonstrates the peptide can affect human pancreatic cell biology in a controlled laboratory environment. It does not demonstrate that the peptide reaches pancreatic cells, crosses beta-cell membranes, enters nuclei, or produces measurable metabolic effects when administered to a human being.

What Would Need to Happen

For human evidence to emerge for Pancragen, a research group would need to:

1. Conduct a pharmacokinetic study establishing that oral or injected Pancragen is absorbed, reaches the pancreas, enters beta cells, and can be detected in pancreatic tissue or blood 2. Conduct a glucose-tolerance or insulin-secretion study in healthy humans establishing that the tetrapeptide produces measurable changes in beta-cell function or glucose homeostasis 3. Conduct a proof-of-concept trial in pre-diabetic or type 2 diabetic subjects measuring fasting glucose, HbA1c, insulin secretion, and beta-cell function over a defined treatment period 4. Conduct a pharmacodynamic study measuring gene expression changes (CXCL12, Hoxa3, or other beta-cell genes) in pancreatic tissue samples or circulating pancreatic markers following Pancragen administration

None of these studies exist or are registered on ClinicalTrials.gov.

Safety, Risks, and Limitations

No Human Safety Data

No formal human safety, toxicology, or pharmacokinetic data exists for Pancragen in Western-accessible literature. The tetrapeptide consists of four amino acids that appear in common dietary proteins—which suggests a favorable theoretical safety profile—but "consists of safe building blocks" is not the same as "demonstrated to be safe in humans."

Theoretical Safety Advantage

Ultrashort peptides are generally considered low-risk because they are rapidly degraded by ubiquitous peptidases present in blood and tissues. A four-amino-acid peptide is expected to have a short half-life (minutes to hours), limited accumulation risk, and low immunogenicity compared to larger peptides. This theoretical safety argument is plausible but has never been formally validated for Pancragen.

The Diabetes-Specific Risk

For readers with diabetes or prediabetes, the most significant risk is not toxicity—it is the replacement of evidence-based therapy with speculative peptide treatment. Structured exercise, dietary intervention, metformin, GLP-1 agonists, and SGLT-2 inhibitors all have human evidence for glucose control and cardiovascular protection. Pancragen has one rat study. Using Pancragen as a substitute for any of these evidence-based therapies would be high-risk.

Unknown Pancreatic Selectivity in Humans

A core claim of the bioregulation paradigm is that a four-amino-acid peptide achieves organ-specific effects. This has never been demonstrated in living humans. It is possible that Pancragen, if absorbed, reaches many tissues—liver, kidney, immune cells, blood vessels—and produces unintended effects in those tissues that have not been characterized. The specificity is theoretical.

Legal and Regulatory Status

FDA Status

Pancragen has never been approved, reviewed, or submitted to the FDA. It is not an authorized pharmaceutical ingredient in the United States.

Russian Status

Pancragen is not a registered pharmaceutical in Russia. Unlike Thymogen (registered 1990), Thymalin (registered ~1982), or other Khavinson products, Pancragen has no pharmaceutical registration in the Russian Federation. It exists only as a research compound.

WADA Status

Pancragen is not specifically listed on the WADA prohibited list. As a synthetic tetrapeptide, it may fall under S2 (Peptide hormones, growth factors, and related substances) depending on classification—but this is ambiguous for a four-amino-acid peptide with no established hormonal activity.

Market Availability

Pancragen is available through research peptide suppliers, typically as lyophilized powder labeled "for research purposes only." Purity, identity, and sterility are not regulated.

Research Protocols and Formulation Considerations

Chemical Composition

Pancragen is a synthetic tetrapeptide: L-Lysyl-L-Glutamyl-L-Aspartyl-L-Tryptophan amide. Molecular weight: ~548 Da. The C-terminal amidation (NH2 group instead of carboxylic acid) is a standard peptide modification intended to enhance stability and potentially improve absorption.

Synthesis

Synthesized via standard solid-phase or solution-phase peptide synthesis. The four-amino-acid sequence is straightforward by modern peptide chemistry standards.

Stability

More stable than smaller dipeptides (Vilon, Thymogen) due to its larger size and the amidation, but still susceptible to degradation by ubiquitous peptidases in biological fluids. The tryptophan residue makes the peptide UV-absorptive and light-sensitive—lyophilized powder should be stored protected from light.

Formulation

Research-grade Pancragen is supplied as lyophilized powder, typically reconstituted with bacteriostatic water or saline for injection. Some vendors may offer capsule formulations intended for oral administration, though bioavailability of a four-amino-acid peptide via oral route is uncertain (the 2007 rat study used oral administration and reported hypoglycemic effects, suggesting oral bioactivity is at least possible in rodents).

Dosing in Published Research

Route of Administration

The published rat study (PMID 18642713) tested both oral (gavage) and intramuscular routes. Oral administration produced the hypoglycemic effect. IM produced the endothelial protection. No human dose has been established.

Doses in Published Studies

PMID 18642713 (rats): Specific doses not provided in the English abstract. The study design was streptozotocin-induced diabetes model, with Pancragen administration via oral or IM route.

Pharmacokinetics

Unknown in humans. Expected half-life is very short (minutes to hours) for a free tetrapeptide due to rapid enzymatic degradation by peptidases. No human pharmacokinetic data exists.

Bioavailability

Oral bioavailability is uncertain. The rat study showed oral Pancragen produced a hypoglycemic effect, suggesting absorption is at least possible in rodents. Bioavailability in humans is unknown. Gastric peptidase degradation is a significant barrier to oral tetrapeptide absorption.

Dosing in Self-Experimentation Communities

WHY NEARLY EMPTY: Pancragen has virtually no community adoption compared to mainstream peptides like BPC-157, TB-500, or MK-677. The Khavinson bioregulator market is niche, and Pancragen is among the least-studied compounds in the family. No systematic community dosing data, dose-response reports, or protocol comparisons exist.

Reported Community Doses

Vendor websites suggest doses in the range of 100–200 mcg/day subcutaneously or via oral capsule formulations. These doses are not derived from any published dose-finding study. They appear to be extrapolated from general bioregulator vendor protocols and marketing materials. Without a human pharmacokinetic or dose-response study, these vendor recommendations have no scientific basis.

Frequency and Duration

Community protocols typically suggest cycles of 10–20 days with rest periods between cycles, following the pattern of other Russian bioregulator supplement protocols. This cycling pattern has no published pharmacological justification.

Combination Stacks

Research into Pancragen combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Pancragen with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) developed by Vladimir Khavinson as the metabolic specialist in the bioregulator family—the only compound targeting the pancreas and glucose homeostasis. In one published animal study (2007), oral Pancragen reduced blood glucose in streptozotocin-diabetic rats. In cell culture, it stimulated expression of pancreatic differentiation markers (CXCL12, Hoxa3) in human embryonic pancreatic cells.

This functional metabolic readout—actual glucose reduction, not just gene expression—makes Pancragen's preclinical story more compelling than most Khavinson bioregulators. The in vitro work with human pancreatic cells is mechanistically plausible. The targeting of the pancreas addresses a massive reader concern (diabetes affects 10% of the global adult population).

But the evidence limitations are severe and unusually consequential. One published study from 2007, authored by the compound's developers. No replication by independent labs. No human pharmacokinetic, dose-finding, or efficacy data. No FDA review, no Russian pharmaceutical registration, no Western regulatory pathway. The bioregulator mechanism—DNA penetration, gene reactivation, pancreas-specific effects—remains theoretical and unvalidated in living humans. And Pancragen enters evidence discussions among readers with high personal stakes—diabetics desperate for effective treatments, not casual users exploring longevity peptides.

Verdict Recapitulation

Pancragen earns "Eyes Open" rather than "Thin Ice" because its preclinical evidence includes a functional metabolic endpoint (glucose lowering in diabetic rats), not just gene expression or in vitro data. The in vitro work with human pancreatic cells is mechanistically sophisticated. The targeting of the pancreas represents the most clinically consequential focus in the entire Cluster S—diabetes is a massive reader concern. But the single-source dependency, the complete absence of human data, the seventeen-year gap since the last published study, and the Khavinson Evidence Problem (no independent replication, no Western regulatory review, contested mechanism) keep it firmly in Tier 4. The high personal stakes for the diabetic reader population make the evidence thinness especially problematic.

For readers considering Pancragen, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Pancragen

Further Reading and Resources

If you want to go deeper on Pancragen, the evidence landscape for khavinson bioregulators peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Khavinson Bioregulators Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Pancragen — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Khavinson VKh et al. "[Pancragen: homeostatic and endothelioprotective effects]." Bulletin of Experimental Biology and Medicine. 2007;144(4):559–562. PMID 18642713
2. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies." Advances in Gerontology. 2012;25(4):696–708. PMID 23734519
3. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results." Advances in Gerontology. 2013;26(1):20–37. PMID 24003726
4. Khavinson VKh, Linkova NS, Trofimova SV. "Peptide bioregulators for cell and tissue repair." Molecules. 2021;26(22):7053. (Theoretical framework and mechanism review)
5. Deigin VI et al. "Development of peptide biopharmaceuticals in Russia." Pharmaceutics. 2022;14(4):716. PMC: 9030433

---